FREE SHIPPING ON ORDERS OVER $150

retatrutide parkinson's disease ๐ŸŽ™๏ธ NEW EPISODE: Retatrutideโ€”The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Eli Lilly's Phase 3 data

$25.35

Quantity
- +
Description

This isnt medical magic its sophisticated biochemistry

retatrutide parkinson's disease NEW EPISODE: RetatrutideThe Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Eli Lilly's Phase 3 data

Comparison to Other GLP-1 Medications Retatrutide's BP reduction exceeds other obesity medications: Semaglutide (Wegovy): -6.2 mmHg systolic Tirzepatide (Zepbound): -8.0 mmHg systolic (15mg, SURMOUNT-1) Retatrutide: -14.0 mmHg systolic The addition of glucagon receptor agonism likely contributes

retatrutide parkinson's disease NEW EPISODE: RetatrutideThe Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Eli Lilly's Phase 3 data

Availability in Germany Wegovy is available in Germany as a solution for injection in a pre-filled pen

retatrutide parkinson's disease NEW EPISODE: RetatrutideThe Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Eli Lilly's Phase 3 data

is an important step in exploring weight-loss options

retatrutide parkinson's disease NEW EPISODE: RetatrutideThe Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Eli Lilly's Phase 3 data

Author Disclosures B.R.S

retatrutide parkinson's disease NEW EPISODE: RetatrutideThe Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Eli Lilly's Phase 3 data

You can register for the webinar here and you can download the 2024 Prohibited List here

retatrutide parkinson's disease NEW EPISODE: RetatrutideThe Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Eli Lilly's Phase 3 data

You may also like

recommand products